/
ACRV
$1.60+$0.09 (+6.29%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$65.1M
43M shares
52-week range
$1.20 – $3.56
17% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-15.12
Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
www.acrivon.com- Employees
- 76
- IPO / List date
- Nov 15, 2022
- HQ
- WATERTOWN, MA
Held by traders on TradeandTell
No one on the platform currently holds ACRV.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 758,440 | $1.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ACRV yet.
